Aftermath Silver Ltd (TSX-V:AAG, OTCQX:AAGFF, FRA:FLM1) announced that it has filed a National Instrument 43-101 technical report that includes a new mineral resource estimate (MRE) for the Berenguela silver-copper-manganese project in the Department of Puno, southern Peru, along with recommendations for additional metallurgical and engineering work aimed at completing a preliminary feasibility study during 2026.
The company reported that it is advancing engineering work focused on commercializing processing flowsheets for silver, copper, and zinc recovery, as well as assessing potential manganese products, including battery-grade manganese sulphate (MnSO₄).
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has closed an $8.8 million equity financing backed by its senior leadership and existing shareholders, as the biotechnology company moves to advance late-stage clinical development of its lead drug candidate.
The company said on Friday after than it has completed its previously disclosed company best efforts registered direct offering of 7,040,000 ordinary shares at a price of $1.25 per share.
Millennial Potash Corp (TSX-V:MLP, OTCQB:MLPNF, FRA:XOD) has earned a ‘Buy’ rating in initial coverage from SCP Equity Research analysts, who highlighted the company’s Banio Potash project in Gabon, West Africa, as a high-potential development in the global potash market.
Millennial Potash acquired the Banio project in 2022. The deposit, located near the coast along a planned port expansion, has been compared geologically to producing solution mines in the neighbouring Republic of Congo.
AST SpaceMobile Inc (NASDAQ:ASTS) shares surged more than 12% on the news that the company had been awarded a contract under the US Missile Defense Agency’s (MDA) Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program.
The SHIELD contract, structured as an indefinite-delivery/indefinite-quantity (IDIQ) agreement, covers a broad range of work including research, development, engineering, prototyping, and operations of critical missile defense systems.
Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in patients treated with its off-the-shelf CD19 CAR-NK cell therapy in Waldenström non-Hodgkin’s lymphoma, adding to recent momentum driven by strong sales growth for its approved immunotherapy Anktiva.
ImmunityBio said on Friday that follow-up from its ongoing Phase 1/2 QUILT-106 study demonstrated sustained complete responses lasting up to 15 months in evaluable patients, with 100% disease control observed to date.
Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF, FRA:1SS) announced that it has completed the integration of blockchain payment provider BitPay across its event technology platforms, alongside a series of backend infrastructure upgrades aimed at improving scalability and efficiency.
The company, which positions itself as an AI-first technology provider for live event solutions, said the BitPay integration strengthens its Phase 2 Blockchain Suite and is now live across its KraftyLab, Map D, and Eventdex platforms. The integration allows clients to settle transactions using more than 100 supported digital assets.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed enrolment in a closely watched mid-stage trial testing whether its experimental drug bezisterim can slow the progression of early Parkinson’s disease, putting the group on track for key data later this year.
The Phase 2 study, known as SUNRISE-PD, has enrolled 60 patients who were diagnosed within the past four years and have not yet been treated with standard levodopa therapy.
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it participated in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held January 12 to 15, 2026, in Nassau, The Bahamas, where the company presented two scientific posters and delivered a Hot Topic Presentation.
The clinical-stage biotechnology company said the presentations included new clinical and preclinical data related to its mental health development programs. The data were shared through two poster presentations, one of which was also selected for the ACNP Hot Topics Session.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the pricing of a registered direct offering expected to raise up to approximately $17.6 million in gross proceeds, including potential proceeds from attached warrants.
Tiziana said the proceeds from the offering are expected to fund the completion of its Phase 2 clinical trials for non-active secondary progressive multiple sclerosis and multiple system atrophy, as well as support top-line data readouts from both studies.
Aftermath Silver Ltd (TSX-V:AAG, OTCQX:AAGFF, FRA:FLM1) was named to the 2026 OTCQX Best 50, an annual ranking of the top-performing companies traded on the OTCQX Best Market.
The OTCQX Best 50 highlights 50 US and international issuers based on their performance over the prior calendar year.
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) is a recovery story with asymmetric upside. In a note published on Friday, Cavendish reiterated its 4p price target, implying more than 300% upside from current levels, after the company confirmed that forecasts for 2026 to 2028 remain intact.
The broker played down a modest revenue miss in 2025, caused by around £0.2 million of contracts slipping into the first quarter of this year, arguing it is largely irrelevant in the context of a much bigger reset now under way.
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) said it is entering 2026 with a sharpened strategy and a focus on turning a £12.6 million sales pipeline into revenues, adding that its balance sheet remained robust.
In an outlook statement accompanying preliminary results, the Guildford-based cancer diagnostics group said its qualified 2026/27 pipeline stood at about £12.6 million, or £4.5 million on a risk-weighted basis.
Cyprium Metals Ltd (ASX:CYM, OTCQB:CYPMF) has entered 2026 with momentum, approving the Phase 1 restart of copper cathode production at the Nifty Copper Complex and securing the funding and approvals needed to transition from developer to near-term producer.
During the December 2025 quarter, the company completed a transformational A$80 million capital raise, refinanced its senior debt facility and maintained a strong cash position of A$75.0 million, providing a clear runway toward first cathode production targeted for mid-2026.
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has secured a major funding milestone after its HOPE® 1 special purpose vehicle (SPV) signed definitive agreements to raise US$32.98 million (AU$49.21m), strengthening the company’s balance sheet and accelerating its lead autism drug candidate toward US FDA approval.
The fundraising values the HOPE® 1 SPV at a post-money valuation of US$65.96 million and assigns Zelira’s retained interest in the vehicle a post-money value of US$26.19 million, underlining growing institutional confidence in the program’s clinical and regulatory pathway.
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has finalised a binding agreement with Marine Biomedical Pty Ltd, lifting its equity stake and securing strategic rights to a next-generation bone regeneration technology as it broadens its regenerative medicine portfolio.
The Perth-based company said it has increased its direct investment in Marine Biomedical from 1.72% to 11.7% for a total consideration of A$1.05 million, converting a previously announced memorandum of understanding into a formal commercial relationship.